返回 
加入收藏
蒲地蓝消炎口服液治疗儿童急性上呼吸道感染的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 蒲地蓝消炎口服液治疗儿童急性上呼吸道感染的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨蒲地蓝消炎口服液治疗儿科急性上呼吸道感染的临床症状消失时间、疗效、安全性，以及对免疫因子的影响。方法：选取重庆市九龙坡区第二人民医院2015年5月－2016年5月收治的急性上呼吸道感染患儿142例，年龄3～17岁，按随机数字表法分为观察组（72例）和对照组（70例）。两组患儿均给予抗病毒及退热等对症治疗，观察组患儿在此基础上给予蒲地蓝消炎口服液，每次10 mL，每日3次，连续给药7 d。比较两组患儿的退热时间和鼻塞、咳嗽、腹泻、咽喉红肿等临床症状的消失时间；检测两组患儿治疗前后血清中肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）和免疫因子（CD3+、CD4+及CD4+/CD8+）水平，并观察两组患儿的临床疗效和药品不良反应发生情况。结果：与对照组比较，观察组患儿的退热时间和鼻塞、咳嗽、腹泻、咽喉红肿等临床症状消失时间均明显缩短（P＜0.05）。治疗前，两组患儿血清中TNF-α、IL-6及免疫因子水平比较差异均无统计学意义（P＞0.05）；治疗后，两组患儿血清中TNF-α、IL-6水平均明显低于治疗前（P＜0.05），CD3+、CD4+及CD4+/CD8+均明显高于治疗前（P＜0.05），其中观察组改善效果明显优于对照组（P＜0.05）。观察组患儿的总有效率明显高于对照组（P＜0.05），两组患儿药品不良反应发生率比较差异无统计学意义（P＞0.05）。结论：蒲地蓝消炎口服液可缩短退热、鼻塞、咳嗽等急性上呼吸道感染症状的消失时间，与抗病毒药合用效果优于单用抗病毒药，且合用与单用安全性相当。 |
| ABSTRACT： | OBJECTIVE： To investigate the time of clinical symptom disappearance， therapeutic efficacy and safety of Pudilan xiaoyan oral liquid and its effects on immune factors in the treatment of pediatric acute upper respiratory tract infection. METHODS： A total of 142 children aged 3-17 with acute upper respiratory tract infection selected from Chongqing Jiulongpo District Second People’s Hospital during May 2015-May 2016 were divided into observation group （72 cases） and control group （70 cases） according to random number tablet. Both groups received symptomatic treatment as antivirus， antipyretic. Observation group was additionally given Pudilan xiaoyan oral liquid 10 mL each time， 3 times a day， treated for consecutive 7 d. The defervescence time， the disappearance time of rhinobyon， coughing， diarrhea and pharynx swelling were compared between 2 groups. The levels of TNF-α， IL-6 and immune factors （CD3+， CD4+ and CD4+/CD8+） were determined in 2 groups before and after treatment. Clinical efficacies and the occurrences of ADR were observed in 2 groups. RESULTS： Compared to control group， the defervescence time， the disappearance time of rhinobyon， coughing， diarrhea， pharynx red and swelling were significantly shortened in observation group （P＜0.05）. Before treatment， there was no statistical significance in the serum levels of TNF-α， IL-6 or immune factors between 2 groups （P＞0.05）. After treatment， the serum levels of TNF-α and IL-6 in 2 groups were significantly lower than before treatment （P＜0.05）. The serum levels of CD3+， CD4+ and CD4+/CD8+ were significantly higher than before treatment of each group（P＜0.05）， while the improvement of observation group was significantly better than that of control group （P＜0.05）. Total response rate of observation group was significantly higher than that of control group （P＜0.05）， but there was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Pudilan xiaoyan oral liquid can shorten the time of acute upper respiratory tract infection disapperance as defervescence， nasal congestion and cough. It combined with antiviral drug is better than antiviral drug alone， but antiviral drug combined with it or alone have same safety. |
| 期刊： | 2018年第29卷第3期 |
| 作者： | 敖李，徐秋 |
| AUTHORS： | AO Li，XU Qiu |
| 关键字： | 蒲地蓝消炎口服液；急性上呼吸道感染；儿童；疗效；症状；临床观察 |
| KEYWORDS： | Pudilan xiaoyan oral liquid； Acute upper respiratory tract infection； Pediatric； Therapeutic efficacy； Symptom； Clinical observation |
| 阅读数： | 929 次 |
| 本月下载数： | 9 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
